07 July 2021
About this Course
Type 2 diabetes (mate huka) currently affects almost 300,000 people in Aotearoa, while approximately 900,000 have prediabetes.
Substantial inequities exist with Māori, Pacific and South-Asian people bearing both the highest burden of disease and the poorest health outcomes.
Following completion of this short course, you will:
- Review diagnosis of type 2 diabetes (T2D) and individualised glycaemic targets.
- Understand non-pharmacological management of T2D.
- Develop knowledge of the non-insulin pharmacological therapies for T2D, focusing on the SGLT2 inhibitors and GLP1 agonists.
Note that this module covers non-insulin management of T2D (mate huka) for adults.
Content created in 2021 by Dr Vicki Mount, MBChB FRNZGP DipPaeds MPH, with expert review by Dr Ryan Paul (BHB, MBChB, FRACP, PhD).
This content was created through an educational grant from Lilly.
|Non-insulin therapies in adults with T2D||Show activities|
|Non-insulin therapies in adults with T2D|